Webb5 juli 2024 · Clear cell carcinoma of the ovary represents 5% to 25% of all epithelial ovarian cancers, depending on geographic location 2. Substantial ethnic and/or racial differences in the distribution of different histological types of … Webb19 maj 2024 · Tissue factor pathway inhibitor 2 (TFPI2) is a novel serum biomarker that discriminates ovarian clear cell carcinoma (CCC) from borderline ovarian tumors (BOTs) and non-clear cell epithelial ovarian cancers (EOCs). Here, we examined the performance of TFPI2 for preoperative diagnosis of CCC. Methods
Clear Cell Ovarian Cancer — Diagnosis and Prognosis
WebbClear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. Webbthe primary effect on the proteome of arid1a-mutated ovarian clear cell carcinoma is downregulation of the mevalonate pathway at the post-transcriptional level running title: … phoebe putney north campus
What Predicts Recurrence and Outcome in Clear Cell Ovarian Carcinoma?
Webb18 sep. 2024 · Clear cell carcinoma has a higher frequency of telomerase reverse transcriptase ( TERT) promoter mutation (5.7%–16.0%) than other histological types of … Webb14 okt. 2024 · Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. Webb20 nov. 2000 · Clear cell carcinoma of the ovary (CCC) originally was termed mesonephroid by Schiller in 1939 because it was believed to originate from mesonephric … ttbh edinburg texas